NCT04109820 Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
| NCT ID | NCT04109820 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2020-03-01 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2020-03-01 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
Eligibility Criteria
Inclusion Criteria: Subjects * African American * Patients with sickle cell anemia * 18 years old or older Control * African American healthy controls * 18 years of age or older Exclusion Criteria: 1. Pregnancy, 2. Known hypertension, 3. Hemodialysis and active obstructive sleep apnea requiring treatment. 4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.
Contact & Investigator
Ramasubramanian Kalpatthi, MD
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT04109820 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04109820 currently recruiting?
Yes, NCT04109820 is actively recruiting participants. Contact the research team at bamnemn2@upmc.edu for enrollment information.
Where is the NCT04109820 trial being conducted?
This trial is being conducted at Pittsburgh, United States, Pittsburgh, United States, Pittsburgh, United States, Pittsburgh, United States and 1 additional location.
Who is sponsoring the NCT04109820 clinical trial?
NCT04109820 is sponsored by University of Pittsburgh. The principal investigator is Ramasubramanian Kalpatthi, MD at University of Pittsburgh. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.